Weight-loss drugs such as Ozempic, made by Denmark’s Novo Nordisk, can reduce rates of opioid and alcohol abuse by up to 50%, according to a new study that supports expectations the drugs can offer greater benefits than just weight and diabetes management.

Ozempic is one of several medications, called glucagon-like peptide-1 receptor agonists or GLP-1 RAs, that are prescribed to treat diabetes, obesity, and other weight-related medical conditions.

New research shows that Ozempic and similar drugs reduce opioid overdoses by 40% and alcohol intoxication by 50% in people with substance use disorders. These medications, often prescribed for diabetes and weight issues,

A new study published today in Addiction suggests that Ozempic and similar medications may be able to help with treatment for opioid and alcohol use disorders.

Diabetes and weight loss drugs like Mounjaro and Ozempic may also help patients suffering from addiction, according to a new study. In the study, published Thursday in the scientific journal Addiction,

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism and opioid addiction, a new study finds.

A study found that prescriptions for GIP/GLP-1 RA drugs may reduce opioid overdose and alcohol intoxication rates in patients with OUD and AUD, offering potential new treatments for addiction.

The weight-loss drugs are linked with reduced rates of excess drinking and opioid overdoses, suggesting they may tamp down substance use cravings too.